Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Zosano Pharma Corporation
ZSANQ
Healthcare
Biotechnology
Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K...
, Annual Reports) filed by Zosano Pharma Corp. Zosano Pharma Corp is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications. The company only operating segment being developing human pharmaceutical products. All the business activities of the firm is functioned through the market of the United States. Its product includes Qtrypta (M207) which is a formulation of zolmitriptan delivered utilizing an Adhesive Dermally-Applied Microarray technology.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (EXPM:ZSANQ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Sep 09, 2019 10:01am
zsan announce RESULTS for qrypta & to file FOR NDA BY FEB 20
Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society September 09, 2019 08:30 ET |
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Aug 14, 2019 10:59am
ZOSAN ANNOUNCES IND FILING PHASE 2/3 CLINICAL STUDY
Zosano Pharma (ZSAN) Announces IND Filing to Initiate Phase 2/3 Clinical Study in Cluster Headache August 14, 2019 9:01 AM EDT Zosano Pharma Corporation (NASDAQ: ZSAN) today
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 23, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Jul 15, 2019 7:27am
ZSAN PRESENT QRYPTA EFFECTIVNESS AT THE AMERICAN HEADACHE AS
Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting Migraine Assessment of Current Therapy (or Migraine-ACT) Scores Highlight the
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Jul 02, 2019 3:01pm
zsan presentation at AMecian heache society july 13th
Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting July 01, 2019 16:05 ET | Source: Zosano Pharma Corporation FREMONT, Calif., July 01, 2019
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Jun 18, 2019 8:44am
ZOSANO PREPARES FOR NDA SUBMISSION OF QTRYPTA DRUG
Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™ Technical Transfer of manufacturing process to CMO signals
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on May 23, 2019 10:08am
ZSAN SUMMARY OF POTENTIAL TIMELINE & CLINICAL RESULTS
Zosano: From Phase 3 To Approval Of A Best-In-Class Migraine Treatment https://seekingalpha.com/article/4265747-zosano-phase-3-approval-best-class-migraine-treatment May 22, 2019 9:40 AM ET Summary
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on May 14, 2019 5:03pm
ZOSANO/ZSAN report earning results Q1 2019
Zosano Pharma Reports First Quarter 2019 Financial Results May 14, 2019 16:05 ET | Source: Zosano Pharma Corporation Multiple catalysts, including QtryptaTM NDA submission
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on May 14, 2019 1:03pm
LongGuy, if you see this, what are you earning expectations?
thx eom
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on May 14, 2019 11:35am
Earning announcement after MKT close tdy.
gl to all, i saw the announcement on this link https://www.cnbc.com/quotes/?symbol=ZSAN
(69)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Apr 16, 2019 10:47am
zsan/zosano positive migraine treatment study
Zosano up 5% premarket on favorable study of migraine treatments Apr. 16, 2019 9:14 AM ET |About: Zosano Pharma Corporation (ZSAN)|By: Douglas W. House, SA News Editor
...more
(4)
•••
Hairybalzonya
X
View Profile
View Bullboard History
Post by
Hairybalzonya
on Feb 11, 2019 10:14pm
Update
Anyone have anything to share about this companies progress?
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >